SCHEMBL5464809

SCHEMBL5464809

CCCCc1ccc(NC(=O)Nc2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ MAPT P10636 5/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ TSHR P16473 1/20 0.54
▸ CYP2C19 P33261 1/20 0.53
▸ HTT P42858 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ LMNA P02545 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ NPC1 O15118 2/20 0.49
▸ ESR2 Q92731 1/20 0.49
▸ NR2F2 P24468 1/20 0.49
▸ MAPK1 P28482 1/20 0.48
▸ GPR119 Q8TDV5 1/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3785257 0.91 MAPT (0.58) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5473427 0.89 NAMPT (0.61) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5467387 0.87 MAPT (0.61) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5462669 0.85 MAPT (0.58) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5458162 0.84 NAMPT (0.56) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3709870 0.84 MAPT (0.61) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL10253108 0.83 MAPT (0.65) NAMPTMAPTMEN1KMT2ANPC1
SCHEMBL5466981 0.83 NAMPT (0.59) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5460938 0.82 NAMPT (0.64) NAMPTSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3124993 0.82 MAPT (0.58) NAMPTSMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 — — US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 NAMPT 324/4885SMN1; SMN2 4424/4885MAPT 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback